SCHEMBL6697974

SCHEMBL6697974

COc1ccc(CC#Cc2cc3c(=O)n(Cc4ccc(F)c(F)c4)c(=O)n(C)c3s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.39
THRB P10828 3/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
ALOX12 P18054 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MMP13 P45452 1/20 0.37
SLC22A8 Q8TCC7 1/20 0.37
HIF1A Q16665 1/20 0.36
PDE1B Q01064 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704876 0.91 MMP13 (0.39) MAPTALDH1A1KMT2APKMTHRB
SCHEMBL6681942 0.90 MMP13 (0.46) MAPTALDH1A1PKMTDP1LMNA
SCHEMBL6916426 0.89 MAPT (0.53) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL6472222 0.88 MMP13 (0.48) MAPTALDH1A1MAPK1THRBTDP1
SCHEMBL6724795 0.84 PARG (0.42) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL7038292 0.84 MMP13 (0.54) MAPTALDH1A1TSHRUSP2PKM
SCHEMBL6471804 0.82 MAPT (0.47) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL6472380 0.80 MAPT (0.48) MAPTALDH1A1TSHRPKMKDM4E
SCHEMBL6917313 0.80 MMP13 (0.50) MAPTALDH1A1TSHRPKMTHRB
SCHEMBL6698004 0.80 MAPT (0.41) MAPTALDH1A1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014916-A1 PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MAPT 4548/4885ALDH1A1 221/4885MEN1 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.